The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors

Journal of Pediatrics

Volumn 149, Issue 1, 2006, Pages 103-111

  Bridges, Esther Marie ^a   Bibby, Michael Charles ^a   Burchill, Susan Ann ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER THERAPY; CANCER TRANSPLANTATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; EWING SARCOMA; FEMALE; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEASIBILITY STUDIES; IN SITU NICK-END LABELING; MICE; MICE, NUDE; REPRODUCIBILITY OF RESULTS; SARCOMA, EWING'S; TUMOR CELLS, CULTURED;

EID: 33746143595     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2006.02.042     Document Type: Article

References (41)

1. Birch J.M., Alston R.D., Kelsey A.M., Quinn M.J., Babb P., and McNally R.J. Classification and incidence of cancers in adolescents and young adults in England, 1979-1997. Br J Cancer 87 (2002) 1267-1274
2. Tarkkanen M., Kiuru-Kuhlefelt S., Blomqvist C., Armengol G., Bohling T., Ekfors T., et al. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 114 (1999) 35-41
3. Askin F.B., Rosai J., Sibley R.K., Dehner L.P., and McAlister W.H. Malignant small cell tumor of the thoracopulmonary region in childhood. a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 43 (1979) 2438-2451
4. Stout A.P. A tumor of the ulnar nerve. Proc NY Pathol Soc 12 (1918) 2-12
5. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc 21 (1921) 17-24
6. Delattre O., Zucman J., Melot T., Garau X.S., Zucker J.M., Lenoir G.M., et al. The Ewing family of tumors. a subgroup of small round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 (1994) 294-299
7. May W.A., Lessnick S.L., Braun B.S., Klemsz M., Lewis B.C., Lunsford L.B., et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13 (1993) 7393-7398
8. Ohno T., Rao V.N., and Reddy E.S. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 53 (1993) 5859-5863
9. May W.A., and Denny C.T. Biology of EWS/FLI and related fusion genes in Ewing's sarcoma and primitive neuroectodermal tumor. Curr Top Microbiol Immunol 220 (1997) 143-150
10. Kovar H., Aryee D., and Zoubek A. The Ewing family of tumors and the search for the Achilles' heel. Curr Opin Oncol 11 (1999) 275-284
11. Cotterill S.J., Parker L., Malcolm A.J., Reid M., More L., and Craft A.W. Incidence and survival for cancer in children and young adults in the North of England, 1968-1995. a report from the Northern Region Young Persons' Malignant Disease Registry. Br J Cancer 83 (2000) 397-403
12. Radford I.R. Imatinib. Novartis. Curr Opin Investig Drugs 3 (2002) 492-499
13. Kane R.C., Bross P.F., Farrell A.T., and Pazdur R. Velcade. US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8 (2003) 508-513
14. Holbeck S.L. Update on NCI in vitro drug screen utilities. Eur J Cancer 40 (2004) 785-793
15. Hollingshead M.G., Alley M.C., Camalier R.F., Abbott B.J., Mayo J.G., Malspeis L., et al. In vivo cultivation of tumor cells in hollow fibers. Life Sci 57 (1995) 131-141
16. Plowman J., Camalier R., Alley M., Sausville E., and Schepartz S. US NCI testing procedures. In: Fiebig H.-H., and Burger A.M. (Eds). Contributions in oncology. relevance of tumour models for anticancer drug development (1999), Karger, Basel 121-135
17. Casciari J.J., Hollingshead M.G., Alley M.C., Mayo J.G., Malspeis L., Miyauchi S., et al. Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J Natl Cancer Inst 86 (1994) 1846-1852
18. Sadar M.D., Akopian V.A., and Beraldi E. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence. Mol Cancer Ther 1 (2002) 629-637
19. Suggitt M., Swaine D.J., Pettit G.R., and Bibby M.C. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clin Cancer Res 10 (2004) 6677-6685
20. Leong C.O., Suggitt M., Swaine D.J., Bibby M.C., Stevens M.F., and Bradshaw T.D. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 3 (2004) 1565-1575
21. Hollingshead M.G., Bonomi C.A., Borgel S.D., Carter J.P., Shoemaker R., Melillo G., et al. A potential role for imaging technology in anticancer efficacy evaluations. Eur J Cancer 40 (2004) 890-898
22. Myatt S.S., Redfern C.P., and Burchill S.A. p38MAPK-dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death. Clin Cancer Res 11 (2005) 3136-3148
23. United Kingdom Co-ordinating Committee on Cancer Research. Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77 (1998) 1-10
24. Camaggi C.M., Comparsi R., Strocchi E., Testoni F., and Pannuti F. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 21 (1988) 216-220
25. Hall L.A., Krauthauser C.M., Wexler R.S., Hollingshead M.G., Slee A.M., and Kerr J.S. The hollow fiber assay. continued characterization with novel approaches. Anticancer Res 20 (2000) 903-911
26. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84 (2001) 1424-1431
27. Hassan S.B., de la Torre M., Nygren P., Karlsson M.O., Larsson R., and Jonsson E. A hollow fiber model for in vitro studies of cytotoxic compounds. activity of the cyanoguanidine CHS 828. Anticancer Drugs 12 (2001) 33-42
28. Triche T.J. Diagnosis of small round cell tumors of childhood. Bull Cancer 75 (1988) 297-310
29. Grier H.E. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am 44 (1997) 991-1004
30. Sutherland R.M. Cell and environment interactions in tumor microregions. the multicell spheroid model. Science 240 (1988) 177-184
31. Groebe K., and Mueller-Klieser W. Distributions of oxygen, nutrient, and metabolic waste concentrations in multicellular spheroids and their dependence on spheroid parameters. Eur Biophys J 19 (1991) 169-181
32. Casciari J.J., Sotirchos S.V., and Sutherland R.M. Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH. J Cell Physiol 151 (1992) 386-394
33. Doroshow J.H. Cancer chemotherapy and biotherapy. principles and practice. In: Chabner B.A., and Longo D.L. (Eds) (1996), Lippincott, Philadelphia 409-434
34. Peterson J.K., and Houghton P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40 (2004) 837-844
35. Phillips R.M., Pearce J., Loadman P.M., Bibby M.C., Cooper P.A., Swaine D.J., et al. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells. implications for anticancer drug screening programs. Cancer Res 58 (1998) 5263-5266
36. Burtles S.S., Newell D.R., Henrar R.E., and Connors T.A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. Eur J Cancer 31 (1995) 408-410
37. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening. empirical to target-driven approaches. Clin Cancer Res 11 (2005) 971-981
38. Houghton P.J., Adamson P.C., Blaney S., Fine H.A., Gorlick R., Haber M., et al. Testing of new agents in childhood cancer preclinical models. meeting summary. Clin Cancer Res 8 (2002) 3646-3657
39. Hollingshead M.G., Plowman J., Alley M.C., Mayo J.G., and Sausville E.A. The hollow fibre assay. In: Fiebig H.-H., and Burger A.M. (Eds). Contributions in oncology. relevance of tumour models for anticancer drug development (1999), Basel, Karger 109-120
40. Decker S., Hollingshead M., Bonomi C.A., Carter J.P., and Sausville E.A. The hollow fibre model in cancer drug screening. the NCI experience. Eur J Cancer 40 (2004) 821-826
41. Jonsson E., Friberg L.E., Karlsson M.O., Hassan S.B., Nygren P., Kristensen J., et al. In vivo activity of CHS 828 on hollow-fiber cultures of primary human tumor cells from patients. Cancer Lett 162 (2001) 193-200